Skip to main content

Table 1 Predicted peptide candidates used for HAdV-specific T-cell screening in healthy donors

From: Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection

HLA class I restriction Sequence [aa] Abbreviation HAdV species: type [cross-reactivity] Responders [EliSpot] T-cell response [reference]
HLA-A*01:01 TDLGQNLLY A01HexonTDLG C: 1, 2, 5 13/18 High [13, 20, 21]
HLA-A*01:01 TNDQSFNDY A01HexonTNDQ A: 31, B: 3, C: 1, 2, 5 2/12 No [21]
HLA-A*01:01 QNDPTVVMY A01HexonQNDP A: 31 0/8 NA
HLA-A*02:01 TLLYVLFEV A02Hexon TLLY A: 31, C:1, 2, 5 28/41 High [13, 22, 23]
HLA-A*02:01 TLAVGDNRV A02HexonTLAV A: 31, B: 3, C: 1, 2, 5 0/5 No [13]
HLA-B*08:01 GLRYRSMLL B08HexonGLRY A: 31, B: 3, C: 1, 2, 5 0/5 Minimal [20]
HLA-B*08:01 DLQDRNTEL B08Hexon DLQD A: 31, B: 3, C: 1, 2, 5 6/27 NA
HLA-A*01:01 STDVASLNY A01Penton STDV C: 1, 2, 5 25/38 NA
HLA-A*01:01 SNDSTFTQY A01PentonSNDS C: 1, 2, 5 0/8 NA
HLA-A*01:01 SSDIASLNY A01PentonSSDI A: 31 0/5 NA
HLA-A*01:01 LTDHGTLPL A01PentonLTDH A: 31, B: 3, C: 1, 2, 5 0/5 NA
HLA-A*02:01 ILHTNMPNV A02Penton ILHT A: 31, C: 1, 2, 5 7/28 NA
HLA-A*02:01 ALGIVSPRV A02PentonALGI A: 31, C: 1, 2, 5 0/6 NA
HLA-A*02:01 GNIPALLDV A02PentonGNIP A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA-A*03:01 VLESDIGVK A03PentonVLES A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA-A*03:01 LLPGCGVDF A03PentonLLPG A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA-B*08:01 NTKYRSWYL B08PentonNTKY A: 31 0/7 NA
HLA-B*08:01 DSKGRSYNL B08Penton DSKG A: 31 9/36 NA
HLA-B*08:01 LTKDKQVEL B08PentonLTKD C: 1, 2 0/5 NA
HLA-B*08:01 DSKKRSYNL B08Penton DSKK C: 1, 2, 5 15/36 NA
  1. Names, sequences and abbreviations of 19 epitope candidates (plus one reference epitope, A01HexonTDLG) predicted for frequent HLA class I alleles and clinically relevant HAdV types. The immunogenicity of epitope candidates was evaluated by pre-screening HAdV-specific T-cell responses to the 19 synthesized peptides in healthy donors using IFN-γ EliSpot assay. Seven of 19 peptide candidates induced HAdV-specific T-cell responses, six of which (highlighted in italic) were classified as immunodominant. The following epitope sequences were published elsewhere: A01HexonTDLG [13, 20, 21], A01HexonTNDQ [21], A02HexonTLLY [13, 22, 23], A02HexonTLAV [13], and B08HexonGLRY [20] (NA not applicable)